A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs AR 101 (Primary) ; Dupilumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 15 Oct 2018 Status changed from not yet recruiting to recruiting, according to an Aimmune Therapeutics media release.
- 21 Sep 2018 Status changed from planning to not yet recruiting.
- 08 May 2018 According to an Aimmune Therapeutics media release, Regeneron / Sanofi expects to initiate this Phase 2 trial of AR101 by year end 2018.